BREZTRI should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition.Available data do not suggest an increased risk of death with use of LABA in patients with COPD When a LABA is used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone. These findings are considered a class effect of LABA monotherapy. Long-acting beta 2-adrenergic agonist (LABA) monotherapy for asthma is associated with an increased risk of asthma-related death.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |